A unified, connected foundation is transforming the future of digital trials
Bio Pharma Dive
NOVEMBER 21, 2022
A holistic approach allows stakeholders to adapt to the ever-increasing number of clinical trials and data points
Sat.Nov 19, 2022 - Fri.Nov 25, 2022
236 
AI will continue to attract investment in near future in the healthcare industry
Pharmaceutical Technology
NOVEMBER 25, 2022
Artificial intelligence (AI) was seen as one of the top current investment priorities and was thought to continue to attract investment in the healthcare sector in the upcoming two years, according to GlobalData's latest report ‘Digital Transformation and Emerging Technology in the Healthcare Industry - 2022 Edition’.
Join 15,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
AI tailors artificial DNA for future drug development
The Pharma Data
NOVEMBER 25, 2022
AI tailors artificial DNA for future drug development. With the help of an AI, researchers at Chalmers University of Technology, Sweden, have succeeded in designing synthetic DNA that controls the cells’ protein production.
What Matters Most: The Trends That Will Shape Pharma Marketing in 2023
Eversana Intouch
NOVEMBER 21, 2022
Download the White Paper. Big concepts. Big platforms. Big words. Big decisions. That’s where we all want to play. It’s easy to toss big words around, though: to be provocative, to hype, to make unsupported claims. It’s far more difficult to be precise, accurate, meaningful. To have impact.
2022 Research: The Rapid Rise of Ocean Freight Visibility
Advertiser: FourKites
Download this a benchmark study from FourKites and The Journal of Commerce exploring how international shippers’ usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19.
FDA approves first gene therapy for hemophilia B
Bio Pharma Dive
NOVEMBER 22, 2022
The treatment, which is for the less common “B” form of the bleeding disorder, will be sold in the U.S. by maker CSL for $3.5 million
Ozempic compensating for Wegovy’s supply shortage due to high demand
Pharmaceutical Technology
NOVEMBER 25, 2022
In recent months, Wegovy (semaglutide), indicated for obesity, has been subjected to widespread supply shortages due to high demand, in addition to manufacturer production problems, with Novo Nordisk intending to relaunch Wegovy by the end of 2022.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Medicines for Malaria Venture and Novartis move to phase 3 trial
Pharma Times
NOVEMBER 23, 2022
Ganaplacide/lumefantrinein new study as world faces emerging resistance to malaria treatments
Cancer drugmaker Plexxikon gets new life as Opna Bio
Bio Pharma Dive
NOVEMBER 21, 2022
Eight months after Daiichi Sankyo shuttered the San Francisco Bay Area subsidiary, Plexxikon’s former CEO is resuscitating its drug research under a new name
NICE questions value and efficacy of five Covid-19 drugs with rejection
Pharmaceutical Technology
NOVEMBER 20, 2022
The UK's National Institute for Health and Care Excellence (NICE) has published a draft guidance that does not recommend the use of five major Covid-19 therapies.
Teva Finalizes Civil Opioid agreement Terms
The Pharma Data
NOVEMBER 22, 2022
Teva Finalizes Civil Opioid agreement Terms. TEL AVIV, Israel & PARSIPPANY,N.J.–( –( BUSINESS WIRE)– Teva Pharmaceuticals, aU.S. chapter of Teva Pharmaceutical diligenceLtd.(
An Innovative & Creative Problem Solver Approach to Selling in the Medical Device Space
Speaker: Steve Goldstein, Sales Leader
Currently in sales or involved in a business that depends on strong sales results? Join Steve Goldstein, Sales Success Coach, Motivational Speaker and Medical Device Sales Leader from Gold Selling LLC. You will absorb critical strategies to become a trusted partner in greater sales success.
Long-COVID personalized medicine enters Phase 2 trial
BioPharma Reporter
NOVEMBER 22, 2022
GeNeuro has recruited the first patients in a Phase 2 trial evaluating temelimab against long-COVID: assessing the efficacy of the treatment for improving cognitive impairment and fatigue. Bio Developments
GSK to pull blood cancer drug from US market after study failure
Bio Pharma Dive
NOVEMBER 22, 2022
The British drugmaker has begun the process of withdrawing its multiple myeloma treatment Blenrep following a request from the FDA
Umoja and IASO partner to develop therapies for haematological malignancies
Pharmaceutical Technology
NOVEMBER 22, 2022
Umoja Biopharma has signed a research agreement with IASO Biotherapeutics (IASO Bio) to develop off-the-shelf therapies for haematological malignancies.
Quadripartite launches a new platform to attack antimicrobial resistance trouble to mortal and beast health and ecosystems
The Pharma Data
NOVEMBER 19, 2022
Quadripartite launches a new platform to attack antimicrobial resistance trouble to mortal and beast health and ecosystems.
Mandatory COVID Vaccination Policy Template
Advertiser: Aggregage
The federal government is developing a rule requiring employers with more than 100 employees ensure their workers are vaccinated or produce a negative COVID test weekly before entering the workplace. So, what can your organization do to prepare? Get Paycor’s COVID Vaccination Policy Template to help communicate important details to your employees.
Brain cancer vaccine succeeds at prolonging survival in Phase 3 trial
BioPharma Reporter
NOVEMBER 21, 2022
A Phase 3 trial for Northwest Biotherapeuticsâs DCVax-L vaccine extended survival in patients with gliobastoma for many months, or in some cases, years: according to new data. Bio Developments
How brands can tap into wellness – lessons from influencers
Bio Pharma Dive
NOVEMBER 21, 2022
Our latest research uncovers new insights on how brands can truly close the wellness gap and grow within their industry sectors
Japan’s MHLW approves Daiichi Sankyo’s breast cancer treatment
Pharmaceutical Technology
NOVEMBER 25, 2022
Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted approval for Daiichi Sankyo ’s Enhertu (trastuzumab deruxtecan) to treat HER2-positive unresectable or recurrent breast cancer in adults.
An arising roadmap to regulating sanitation services
The Pharma Data
NOVEMBER 19, 2022
An arising roadmap to regulating sanitation services. Kate Medlicott( WHO), Yvonne Magawa( ESAWAS), Peter Mutale( NAWASCO), Chola Mbilima( NWASCO), Sam Drabble( WSUP), Mohammad Said Al Hmaidi( WSRC), Massa Antoine Traore( MoESSD, Mali), Jelena Krsti?(
Study brings personalised immunotherapy prescriptions closer
Pharma Times
NOVEMBER 23, 2022
Research showed that prescribing based solely on levels of proteins present is unlikely to be suitable
Teva taps Sandoz veteran to take over CEO post from Schultz
Bio Pharma Dive
NOVEMBER 21, 2022
Richard Francis will take over for the retiring Kåre Schultz on Jan. He’ll face major challenges at Teva, including opioid settlements, biosimilar launches and reducing the company’s debt
FDA grants approval for CSL’s haemophilia B gene therapy
Pharmaceutical Technology
NOVEMBER 23, 2022
The US Food and Drug Administration (FDA) has granted approval for CSL Behring’s adeno-associated virus vector-based gene therapy, Hemgenix (etranacogene dezaparvovec), to treat haemophilia B (congenital Factor IX deficiency) in adult patients.
Statement on Allergan Nationwide agreement to Resolve Opioid-Affiliated Claims
The Pharma Data
NOVEMBER 22, 2022
Statement on Allergan Nationwide agreement to Resolve Opioid-Affiliated Claims. Allergan has agreed to a civil agreement moment to resolve opioid-affiliated claims with countries and their separate services and special sections, handed that all conditions are satisfied.
Depressive therapy Spravato demonstrates superior efficacy
Pharma Times
NOVEMBER 25, 2022
Research supports use of Spravato nasal spray in adults with major depressive disorder
Merck to buy blood cancer biotech Imago for $1.35B
Bio Pharma Dive
NOVEMBER 21, 2022
The deal is Merck’s second notable acquisition of a cancer drugmaker in the past year and a half, part of a strategy to diversify its pipeline beyond top-selling immunotherapy Keytruda
XtalPi and CK Life Sciences to develop AI-driven tumour vaccine R&D platform
Pharmaceutical Technology
NOVEMBER 25, 2022
XtalPi has entered a strategic partnership with CK Life Sciences for artificial intelligence (AI)-driven tumour vaccine research and development (R&D). Under the collaboration, the companies will utilise their capabilities to co-develop a new AI tumour vaccine R&D platform.
The digital app released to boost physical exertion – and help get children moving
The Pharma Data
NOVEMBER 19, 2022
The digital app released to boost physical exertion – and help get children moving.
Bristol Myers Squibb immunotherapy-chemo combination gets NICE recommendation
Pharma Times
NOVEMBER 25, 2022
Treatment involves adults with certain forms of advanced stomach and oesophageal cancer
The next era of Greater Boston’s biotech boom
Bio Pharma Dive
NOVEMBER 22, 2022
Over the past two decades, the Cambridge area has become a nerve center for biotech in the U.S. But to stay relevant and accessible, the hub is expanding to the suburbs
Japan grants emergency regulatory approval for Shionogi’s Covid-19 drug
Pharmaceutical Technology
NOVEMBER 22, 2022
The Ministry of Health, Labour and Welfare (MHLW) in Japan has granted emergency regulatory approval for Shionogi ’s new anti-SARS-CoV-2 drug, Xocova (ensitrelvir fumaric acid, S-217622), for Covid-19.
Taking the right forecasting approach for rare diseases
Pharma Phorum
NOVEMBER 25, 2022
There are approximately 7,000 different types of rare disease and researchers estimate that there are more than 300 million people worldwide living with such a condition, according to the National Institutes of Health (NIH).
Storm doses first patient with solid tumour drug candidate
Pharma Times
NOVEMBER 24, 2022
Candidate is first molecule targeting an RNA methyltransferase enzyme to enter development
Biotech ObsEva sells drug rights to forestall funding crunch
Bio Pharma Dive
NOVEMBER 22, 2022
In an effort to extend its cash runway and keep its stock listing, ObsEva is offloading rights to an experimental preterm labor drug in a deal with Xoma
Merck agrees to acquire Imago for $1.35bn
Pharmaceutical Technology
NOVEMBER 21, 2022
Merck (MSD outside North America) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences, through a subsidiary, for $36.00 per each share in cash or for a total equity price of nearly $1.35bn.
Sporting a $3.5M price tag, CSL and uniQure's hemophilia B gene therapy crosses FDA finish line
Fierce Pharma
NOVEMBER 23, 2022
Sporting a $3.5M price tag, CSL and uniQure's hemophilia B gene therapy crosses FDA finish line. zbecker. Wed, 11/23/2022 - 10:10
Let's personalize your content